
    
      Subjects will be enrolled in 3 age strata. Subjects including and above two years of age will
      receive either GSK Biologicals meningococcal vaccine 134612 or Mencevax™ ACWY, subjects below
      two years of age will receive either GSK Biologicals meningococcal vaccine 134612 or
      Meningitec™. All subjects will have 7 blood samples taken: prior and one month after
      vaccination and one, two, three, four and five years after vaccination.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act,
      September 2007.
    
  